Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Contemporary approach to active surveillance for favorable risk prostate cancer.

Klotz L.

Asian J Urol. 2019 Apr;6(2):146-152. doi: 10.1016/j.ajur.2018.12.003. Epub 2018 Dec 15. Review.

2.

Active Surveillance for Prostate Cancer: How to Do It Right.

Garisto JD, Klotz L.

Oncology (Williston Park). 2017 May 15;31(5):333-40, 345. Review.

3.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041. Epub 2010 May 15.

PMID:
20478589
4.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

5.

Active surveillance: the Canadian experience with an "inclusive approach".

Klotz L.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):234-41. doi: 10.1093/jncimonographs/lgs042.

6.

Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.

Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS.

J Urol. 2017 Mar;197(3 Pt 1):632-639. doi: 10.1016/j.juro.2016.09.070. Epub 2016 Sep 14.

7.

Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.

Perlis N, Sayyid R, Evans A, Van Der Kwast T, Toi A, Finelli A, Kulkarni G, Hamilton R, Zlotta AR, Trachtenberg J, Ghai S, Fleshner NE.

J Urol. 2017 Jan;197(1):75-83. doi: 10.1016/j.juro.2016.07.076. Epub 2016 Jul 22.

PMID:
27457260
8.

Active surveillance: the Canadian experience.

Klotz L.

Curr Opin Urol. 2012 May;22(3):222-30. doi: 10.1097/MOU.0b013e328352598c. Review.

PMID:
22453335
9.

Active surveillance versus radical treatment for favorable-risk localized prostate cancer.

Klotz L.

Curr Treat Options Oncol. 2006 Sep;7(5):355-62. Review.

PMID:
16904052
10.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A.

J Urol. 2016 Dec;196(6):1651-1658. doi: 10.1016/j.juro.2016.06.102. Epub 2016 Aug 26.

PMID:
27569437
11.
12.

Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.

Yamamoto T, Musunuru HB, Vesprini D, Zhang L, Ghanem G, Loblaw A, Klotz L.

J Urol. 2016 May;195(5):1409-1414. doi: 10.1016/j.juro.2015.11.075. Epub 2015 Dec 18.

PMID:
26707510
13.

Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.

Loeb S, Berglund A, Stattin P.

J Urol. 2013 Nov;190(5):1742-9. doi: 10.1016/j.juro.2013.05.054. Epub 2013 May 30.

PMID:
23727309
15.

Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

JAMA Oncol. 2017 Oct 1;3(10):1393-1398. doi: 10.1001/jamaoncol.2016.3600.

16.

Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23.

PMID:
24071481
17.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

18.

Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.

Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, Chung BH.

Jpn J Clin Oncol. 2013 May;43(5):553-8. doi: 10.1093/jjco/hyt041. Epub 2013 Apr 11.

PMID:
23580758
19.

Active surveillance: patient selection.

Klotz L.

Curr Opin Urol. 2013 May;23(3):239-44. doi: 10.1097/MOU.0b013e32835f8f6b. Review.

PMID:
23548978
20.

Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.

Tsang CF, Tsu JH, Lai TC, Wong KW, Ho BS, Ng AT, Ma WK, Yiu MK.

Hong Kong Med J. 2017 Dec;23(6):609-15. doi: 10.12809/hkmj166194. Epub 2017 Oct 13.

Supplemental Content

Support Center